These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33936221)

  • 1. Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by Z
    Siavoshinia L; Jamalan M; Zeinali M; Pourshohod A; Koushki M; Moradipoodeh B; Mohammadzadeh G
    Iran J Pathol; 2021; 16(2):109-118. PubMed ID: 33936221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
    Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
    Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
    Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
    Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological Responses against HER2-targeted Idarubicin-ZHER2 Conjugate in BALB/c Mice.
    Siavoshinia L; Jamalan M; Zeinali M; Mohammadzadeh G
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(5):501-510. PubMed ID: 32245294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.
    Damiani I; Castiglioni S; Sochaj-Gregorczyk A; Bonacina F; Colombo I; Rusconi V; Otlewski J; Corsini A; Bellosta S
    Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34439990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
    Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
    J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model.
    Jiao H; Zhao X; Liu J; Ma T; Zhang Z; Zhang J; Wang J
    Nucl Med Biol; 2019; 68-69():31-39. PubMed ID: 30578135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
    Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
    J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.
    Sochaj-Gregorczyk AM; Ludzia P; Kozdrowska E; Jakimowicz P; Sokolowska-Wedzina A; Otlewski J
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
    Dong D; Xia G; Li Z; Li Z
    Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule
    Liu Y; Vorobyeva A; Orlova A; Konijnenberg MW; Xu T; Bragina O; Loftenius A; Rosander E; Frejd FY; Tolmachev V
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution.
    Ding H; Xu T; Zhang J; Tolmachev V; Oroujeni M; Orlova A; Gräslund T; Vorobyeva A
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33806887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
    Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.